20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunitybio Inc (IBRX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 684 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, IBRX reported $113M in revenue and ($351M) in net income.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Interactive charts & full statements → Open the IBRX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $165M | $113M | $15M | $1M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $1M | $1M |
| Gross Profit | $157M | $113M | $15M | $1M | $0M | $1M | $1M | ($9M) | $3M | $0M | $0M | $0M | $1M | $0M |
| Gross Margin % | 95.2% | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -20858.1% | 6717.0% | 100.0% | 100.0% | 100.0% | 100.0% | 57.8% |
| Operating Income (EBIT) | ($253M) | ($256M) | ($344M) | ($362M) | ($351M) | ($330M) | ($221M) | ($67M) | ($98M) | ($99M) | ($124M) | ($239M) | ($6M) | ($2M) |
| Operating Margin % | -153.3% | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -155597.7% | -209338.3% | -220266.7% | -282954.6% | -101218.6% | -969.1% | -378.2% |
| Net Income | ($992M) | ($351M) | ($414M) | ($583M) | ($417M) | ($347M) | ($222M) | ($66M) | ($96M) | ($96M) | ($121M) | ($237M) | ($6M) | ($2M) |
| Net Margin % | -601.2% | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -152997.7% | -204736.2% | -214273.3% | -274565.9% | -100371.2% | -969.3% | -341.2% |
| EBITDA | ($889M) | ($224M) | ($264M) | ($479M) | ($352M) | ($321M) | ($204M) | ($57M) | ($87M) | ($91M) | ($118M) | ($236M) | ($6M) | ($2M) |
| Earnings Per Share (EPS) | $-0.97 | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.58 | $-0.17 | $-0.30 | $-0.30 | $-0.37 | $-0.83 | $-0.02 | $-0.01 |
| Shares Outstanding (M) | 1,050M | 920M | 700M | 509M | 400M | 389M | 383M | 383M | 325M | 322M | 328M | 286M | 316M | 316M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $51M | $44M | $38M | $32M | $26M | $17M | $8M | $6M |
| Gross Profit | $51M | $44M | $34M | $28M | $26M | $16M | $8M | $6M |
| Gross Margin % | 99.4% | 99.5% | 88.9% | 87.1% | 99.5% | 99.7% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($62M) | ($70M) | ($65M) | ($56M) | ($71M) | ($64M) | ($69M) | ($80M) |
| Operating Margin % | -120.4% | -157.9% | -168.9% | -173.5% | -269.8% | -390.1% | -919.0% | -1314.3% |
| Net Income | ($230M) | ($633M) | ($62M) | ($67M) | ($93M) | ($130M) | ($59M) | ($86M) |
| Net Margin % | -449.6% | -1431.4% | -161.8% | -209.8% | -350.3% | -784.9% | -783.4% | -1404.0% |
| EBITDA | ($222M) | ($600M) | ($31M) | ($36M) | ($60M) | ($97M) | ($40M) | ($41M) |
| Earnings Per Share (EPS) | $-0.22 | $-0.62 | $-0.06 | $-0.07 | $-0.10 | $-0.15 | $-0.08 | $-0.12 |
| Shares Outstanding (M) | 1,050M | 1,027M | 990M | 947M | 888M | 853M | 735M | 698M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($281M) | ($305M) | ($391M) | ($367M) | ($338M) | ($274M) | ($172M) | ($152M) | ($63M) | ($49M) | ($39M) | ($25M) | ($5M) | ($1M) |
| Capital Expenditures (CapEx) | $7M | $4M | $7M | $31M | $78M | $34M | $2M | $4M | $13M | $35M | $7M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($289M) | ($309M) | ($398M) | ($397M) | ($416M) | ($308M) | ($173M) | ($156M) | ($76M) | ($84M) | ($45M) | ($28M) | ($6M) | ($1M) |
| FCF Margin % | -175.2% | -272.6% | -2700.1% | -63881.2% | -173196.2% | -32974.5% | -28660.0% | -363711.6% | -162729.8% | -185766.7% | -102620.5% | -11672.0% | -881.9% | -111.8% |
| Dividends Paid | — | — | — | — | $1M | $334M | $4M | $2M | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($67M) | ($75M) | ($70M) | ($69M) | ($80M) | ($86M) | ($85M) | ($99M) |
| Capital Expenditures (CapEx) | $3M | $2M | $1M | $1M | $1M | $1M | $2M | $3M |
| Free Cash Flow (FCF) | ($70M) | ($77M) | ($72M) | ($70M) | ($81M) | ($87M) | ($87M) | ($102M) |
| FCF Margin % | -137.2% | -174.5% | -187.2% | -217.3% | -305.9% | -526.9% | -1155.4% | -1663.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $629M | $502M | $383M | $504M | $362M | $469M | $221M | $143M | $182M | $250M | $317M | $367M | $61M | $2M |
| Cash & Cash Equivalents | $76M | $88M | $143M | $265M | $105M | $181M | $35M | $16M | $17M | $24M | $8M | $176M | $59M | $0M |
| Total Liabilities | $1.7B | $1.0B | $871M | $1.1B | $812M | $713M | $340M | $22M | $36M | $32M | $24M | $11M | $2M | $5M |
| Total Debt (Short + Long-Term) | $782M | $486M | $469M | $687M | $676M | $609M | $259M | $4M | $1M | $0M | $0M | $0M | $0M | $2M |
| Total Shareholders' Equity | ($1.0B) | ($500M) | ($489M) | ($587M) | ($447M) | ($242M) | ($120M) | $121M | $146M | $219M | $293M | $356M | $58M | ($3M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IBRX viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms